Fenimore Asset Management Has Lowered Its Mednax (MD) Stake; Ardsley Advisory Partners Upped Progenics Pharmaceuticals In (PGNX) Stake By $9.80 Million

February 15, 2018 - By Linda Rogers

Fenimore Asset Management Inc decreased Mednax Inc. (MD) stake by 18.02% reported in 2017Q3 SEC filing. Fenimore Asset Management Inc sold 157,455 shares as Mednax Inc. (MD)’s stock declined 21.94%. The Fenimore Asset Management Inc holds 716,505 shares with $30.90 million value, down from 873,960 last quarter. Mednax Inc. now has $5.11 billion valuation. The stock increased 0.73% or $0.4 during the last trading session, reaching $55.16. About 41,391 shares traded. MEDNAX, Inc. (NYSE:MD) has declined 18.20% since February 15, 2017 and is downtrending. It has underperformed by 34.90% the S&P500.

Ardsley Advisory Partners increased Progenics Pharmaceuticals In (PGNX) stake by 274.51% reported in 2017Q3 SEC filing. Ardsley Advisory Partners acquired 1.40 million shares as Progenics Pharmaceuticals In (PGNX)’s stock declined 34.18%. The Ardsley Advisory Partners holds 1.91M shares with $14.06 million value, up from 510,000 last quarter. Progenics Pharmaceuticals In now has $407.57 million valuation. The stock increased 1.40% or $0.08 during the last trading session, reaching $5.8. About 88,298 shares traded. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has risen 48.41% since February 15, 2017 and is uptrending. It has outperformed by 31.71% the S&P500.




Investors sentiment decreased to 1.11 in Q3 2017. Its down 0.18, from 1.29 in 2017Q2. It worsened, as 22 investors sold PGNX shares while 34 reduced holdings. 16 funds opened positions while 46 raised stakes. 58.90 million shares or 4.84% less from 61.90 million shares in 2017Q2 were reported. Missouri-based Stifel Corp has invested 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). State Board Of Administration Of Florida Retirement Systems reported 45,340 shares. Royal Bank & Trust Of Canada reported 6,338 shares stake. Price T Rowe Assocs Md has invested 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Nationwide Fund Advisors owns 0% invested in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) for 38,428 shares. Northern Trust holds 0% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) for 886,616 shares. Fisher Asset Mgmt Limited Company stated it has 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Hall Laurie J Trustee reported 920 shares. Goldman Sachs has invested 0% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Sg Americas Secs Limited Co stated it has 14,530 shares or 0% of all its holdings. Federated Invsts Inc Pa reported 0.22% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Guggenheim Capital holds 0% or 285,574 shares. Kbc Group Nv owns 234,777 shares. The New York-based Group has invested 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Principal Fin Grp, Iowa-based fund reported 588,754 shares.

Ardsley Advisory Partners decreased First Solar Inc (Call) (NASDAQ:FSLR) stake by 40,000 shares to 10,000 valued at $459,000 in 2017Q3. It also reduced United Rentals Inc (NYSE:URI) stake by 5,000 shares and now owns 75,000 shares. Alphabet Inc was reduced too.

Among 5 analysts covering Progenics Pharm (NASDAQ:PGNX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Progenics Pharm had 11 analyst reports since August 6, 2015 according to SRatingsIntel. Jefferies maintained the stock with “Buy” rating in Tuesday, September 26 report. The firm earned “Buy” rating on Thursday, October 27 by Aegis Capital. The rating was maintained by Needham with “Buy” on Friday, August 7. Needham upgraded it to “Strong Buy” rating and $14 target in Monday, February 6 report. The stock of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) earned “Buy” rating by Jefferies on Thursday, June 8. The rating was upgraded by Jefferies to “Buy” on Friday, October 23. The firm earned “Buy” rating on Thursday, August 6 by Brean Capital. The stock of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has “Buy” rating given on Wednesday, August 9 by Cantor Fitzgerald. The firm earned “Buy” rating on Friday, August 7 by Zacks. The firm has “Buy” rating given on Tuesday, June 20 by Needham.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.